Transendocardial Mesenchymal Stem Cells and Mononuclear Bone Marrow Cells for Ischemic Cardiomyopathy

Heldman, Alan W.; Di Fede, Darcy L.; Fishman, Joel E.; Zambrano, Juan P.; Trachtenberg, Barry H.; Karantalis, Vasileios; Mushtaq, Muzammil; Williams, Adam R.; Suncion, Viky Y.; McNiece, Ian K.; Ghersin, Eduard; Soto, Victor; Lopera, Gustavo; Miki, Roberto; Willens, Howard; Hendel, Robert; Mitrani, Raul; Pattany, Pradip; Feigenbaum, Gary; Oskouei, Behzad
January 2014
JAMA: Journal of the American Medical Association;1/1/2014, Vol. 311 Issue 1, p62
Academic Journal
IMPORTANCE Whether culture-expanded mesenchymal stem cells or whole bone marrow mononuclear cells are safe and effective in chronic ischemic cardiomyopathy is controversial. OBJECTIVE To demonstrate the safety of transendocardial stem cell injection with autologous mesenchymal stem cells (MSCs) and bone marrow mononuclear cells (BMCs) in patients with ischemic cardiomyopathy. DESIGN, SETTING, AND PATIENTS A phase 1 and 2 randomized, blinded, placebo-controlled study involving 65 patients with ischemic cardiomyopathy and left ventricular (LV) ejection fraction less than50%(September 1, 2009-July 12, 2013). The study compared injection of MSCs (n=19) with placebo (n = 11) and BMCs (n = 19) with placebo (n = 10), with 1 year of follow-up. INTERVENTIONS Injections in 10 LV sites with an infusion catheter. MAIN OUTCOMES AND MEASURES Treatment-emergent 30-day serious adverse event rate defined as a composite of death, myocardial infarction, stroke, hospitalization for worsening heart failure, perforation, tamponade, or sustained ventricular arrhythmias. RESULTS No patient had a treatment-emergent serious adverse events at day 30. The 1-year incidence of serious adverse events was 31.6%(95%CI, 12.6%to 56.6%) for MSCs, 31.6% (95%CI, 12.6%-56.6%) for BMCs, and 38.1%(95%CI, 18.1%-61.6%) for placebo. Over 1 year, the Minnesota Living With Heart Failure score improved with MSCs (-6.3; 95%CI, -15.0 to 2.4; repeated measures of variance, P=.02) and with BMCs (-8.2; 95%CI, -17.4 to 0.97; P=.005) but not with placebo (0.4; 95%CI, -9.45 to 10.25; P=.38). The 6-minute walk distance increased with MSCs only (repeated measures model, P = .03). Infarct size as a percentage of LV mass was reduced by MSCs (-18.9%; 95%CI, -30.4 to -7.4; within-group, P = .004) but not by BMCs (-7.0%; 95%CI, -15.7%to 1.7%; within-group, P = .11) or placebo (-5.2%; 95%CI, -16.8%to 6.5%; within-group, P = .36). Regional myocardial function as peak Eulerian circumferential strain at the site of injection improved with MSCs (-4.9; 95%CI, -13.3 to 3.5; within-group repeated measures, P = .03) but not BMCs (-2.1; 95%CI, -5.5 to 1.3; P = .21) or placebo (-0.03; 95%CI, -1.9 to 1.9; P = .14). Left ventricular chamber volume and ejection fraction did not change. CONCLUSIONS AND RELEVANCE Transendocardial stem cell injection with MSCs or BMCs appeared to be safe for patients with chronic ischemic cardiomyopathy and LV dysfunction. Although the sample size and multiple comparisons preclude a definitive statement about safety and clinical effect, these results provide the basis for larger studies to provide definitive evidence about safety and to assess efficacy of this new therapeutic approach. TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT00768066


Related Articles

  • Stem Cell Therapy for Multiple Sclerosise. Nabavi, S. M. // Cell Journal (Yakhteh);Summer 2013 Supplement 1, Vol. 15 Issue Sup 1, p25 

    Objective: Although DMDs reduce the rate of relapses of MS, there is no effective means to stop the progression of disability or induce rebuilding of the destroyed myelin and axons. Adult bone marrow derived stromal cells (MSC) were shown to induce immunomodulatory and neuroregenerative effects...

  • Development of cellular therapy for the treatment of stress urinary incontinence. Wang, Hung-Jen; Chuang, Yao-Chi; Chancellor, Michael // International Urogynecology Journal;Sep2011, Vol. 22 Issue 9, p1075 

    Stress urinary incontinence (SUI) is highly prevalent and associated with a reduced quality of life. An intact rhabdosphincter at the mid-urethra is mandatory to maintain urinary continence. Adult stem cell injection therapy for the regenerative repair of an impaired sphincter is currently at...

  • MSCs Isolated From Patients With Ischemic Vascular Disease Have Normal Angiogenic Potential. Sanz-Nogués, Clara; O'Brien, Timothy // Molecular Therapy;Nov2014, Vol. 22 Issue 11, p1888 

    The authors discuss aspects of stem cell therapy using bone marrow-derived mesenchymal stem cells (BM-MSCs) as an alternative treatment for revascularization in patients with critical limb ischemia (CLI). Citing the study by Gremmels and colleagues within the issue, they explore the therapeutic...

  • Enhancing Effect of Glucose Microspheres in the Viability of Human Mesenchymal Stem Cell Suspensions for Clinical Administration. Gálvez, Patricia; Martín, Maria; Calpena, Ana; Tamayo, Juan; Ruiz, Maria; Clares, Beatriz // Pharmaceutical Research;Dec2014, Vol. 31 Issue 12, p3515 

    Purpose: A critical limiting factor of cell therapy is the short life of the stem cells. In this study, glucose containing alginate microspheres were developed and characterized to provide a sustained release system prolonging the viability of human mesenchymal stem cells (hMSCs) in a suspension...

  • Regenerative medicine -- are we there yet? French, Peter // Australasian Biotechnology;Mar2016, Vol. 26 Issue 1, p41 

    The article discusses regenerative medicine through stem cell treatment. Topics include stem cell types such as bone marrow stem cells and mesenchymal stem cells, progress and challenges of stem cell treatment such as cell disintegration with the tissue and regeneration of differentiated cells,...

  • Mesenchymal Stem Cells as Mediators of Neural Differentiation. Hardy, Steven A.; Maltman, Daniel J.; Przyborski, Stefan A. // Current Stem Cell Research & Therapy;Jan2008, Vol. 3 Issue 1, p43 

    Mesenchymal stem cells (MSCs) represent a promising source of material for autologous cell transplantation therapies, in particular, their potential use for the treatment of damaged nervous tissue. Much of the work in this area has focused on the transplantation of MSCs into animal models of...

  • Preclinical Biosafety Evaluation of Cell-based Therapies: Emerging Global Paradigms. Basu, Joydeep; Assaf, Basel T.; Bertram, Timothy A.; Rao, Mahendra // Toxicologic Pathology;Jan2015, Vol. 43 Issue 1, p115 

    Cell-based therapies have the potential to treat a diversity of disease conditions, many representing significant and long-standing unmet medical needs. Certain properties of cell-based therapies, such as differentiation potential and proliferative potential, present safety concerns uniquely...

  • Adult Stem Cell Responses to Nanostimuli. Tsimbouri, Penelope M. // Journal of Functional Biomaterials;2015, Vol. 6 Issue 3, p598 

    Adult or mesenchymal stem cells (MSCs) have been found in different tissues in the body, residing in stem cell microenvironments called "stem cell niches". They play different roles but their main activity is to maintain tissue homeostasis and repair throughout the lifetime of an organism. Their...

  • A prospective, non-randomized, no placebo-controlled, phase Ib clinical trial to study the safety of the adipose derived stromal cells-stromal vascular fraction in idiopathic pulmonary fibrosis. Argyris Tzouvelekis; Paspaliaris, Vassilis; Koliakos, George; Ntolios, Paschalis; Bouros, Evangelos; Anastasia Oikonomou; Athanassios Zissimopoulos; Nikolaos Boussios; Brian Dardzinski; Dimitrios Gritzalis; Antonis Antoniadis; Marios Froudarakis; Kolios, George; Bouros, Demosthenes // Journal of Translational Medicine;2013, Vol. 11 Issue 1, p1 

    Introduction: Regenerative medicine and particular adult stem cells represent an alternative option with several fruitful therapeutic applications in patients suffering from chronic lung diseases including idiopathic pulmonary fibrosis (IPF). Nevertheless, lack of knowledge regarding the origin...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics